您好，欢迎光临世界标品！ 登录 注册（订药物标准品请用邮件联系我们）

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索（中英文）：
世界各国官方药品目录搜索（英文）：
世界标品医药知识搜索（中英文）：

美国药房|加拿大药房|英国药房|瑞士药房|澳大利亚药房|新西兰药房|香港药房|印度药房|新加坡药房|俄罗斯药房|法律的依据
日本药房|德国药房|孟加拉药房|巴西药房|欧洲共同体药房|土耳其药房|以色列药房|法国药房|罗马尼亚药房|墨西哥药房|爱尔兰药房
荷兰药房|意大利药房|保加利亚药房|南非药房|芬兰药房|挪威药房
联系方式
国内客服电话：
国际免费电话：

咨询邮箱：
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 调节水、电解质药->高磷血症
处方药:处方药
包装规格: 500毫克/片 90片/盒
计价单位:
   
生产厂家英文名:
 VIFOR FRESENIUS
该药品相关信息网址1:
 http://reference.medscape.com/drug/velphoro-sucroferric-oxyhydroxide-999889
该药品相关信息网址2:
 https://www.velphoro.us/
 原产地英文商品名:
 Velphoro 500mg chewable tablets 90 tabs
原产地英文药品名:
 SUCROFERRIC OXYHYDROXIDE
中文参考商品译名:
 Velphoro咀嚼片 500毫克/片 90片/盒
中文参考药品译名:
 羥基氧化蔗糖鐵
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
 Chronic kidney dialysis patients with hyperphosphatemia
 临床试验期:
 完成
中文适应病症参考翻译1:
 慢性肾病透析患者高磷血症
药品信息:
November 28, 2013, FDA approved serum phosphorus levels Velphoro ® is used to control chronic kidney dialysis patients. Velphoro ® Vifor Pharma APIs will be produced at the factory in Switzerland, Fresenius Medical Health (North America), the company responsible for sales in the U.S. market in 2014. Velphoro ® was developed by Vifor Pharma. 2011, Velphoro ®'s ownership transferred to Galenica (July this year the FDA approved its Injectafer for the treatment of iron deficiency anemia) and Fresenius Medical Care, a joint venture Vifor Fresenius Medical Care Renal Pharma (Vifor Fresenius Medical Care). Velphoro ® was approved based on primary and secondary endpoints of the Phase III clinical trial results achieved. The Phase III clinical trial participation of more than 1000 subjects. The results show that, compared to sevelamer carbonate (the current standard therapy), smaller doses of Velphoro ® can successfully control hyperphosphatemia. 52 weeks of treatment, control hyperphosphatemia, an average of only 3.3 Velphoro ®, and the security is good. Hyperphosphatemia in chronic kidney disease (CKD) is a common complication is caused by secondary hyperparathyroidism, an important factor in changing the deposition of calcium and phosphorus, vitamin D metabolism, renal osteodystrophy, and coronary heart closely related to serious cardiovascular complications valvular calcification. The recommended dose Velphoro ® is three times daily after meals 1. Market outlook: Chronic kidney dialysis patients to eat a daily average of 19 drugs, of which about half are phosphate binders, significantly improved medication compliance, currently accepted medical standards with advanced chronic kidney disease patients on dialysis Sanofi's (Sanofi) of Renvela (sevelamer carbonate, Sanofi acquisition of Genzyme gain) compared with the advantages of a small dose. Renvela (sevelamer carbonate) in the first three quarters of sales in the U.S. was 6.5 billion U.S. dollars, ranking in sales of around 70 TOP100, sevelamer hydrochloride in 2008 worldwide sales of $ 850 million, the listing is expected to rapidly after Velphoro seize the market than Renvela, becoming one billion dollars in blockbuster drug is relatively easy to achieve.
更新日期: 2014-07-20
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间：太平洋时间18:00-24:00
国内客服电话：     国际免费电话：
友情提示：以上电话为免费电话，无需您承担任何费用，世界标品提供中文客服，请您放心拨打！
电子邮箱：sciteck.hongkong@gmail.com, 15901965168@163.com